The Boston-based Dana-Farber Cancer Institute has notified research journals that it desires to retract six studies and correct 31 papers — including those co-authored by top executives — as part of an ongoing probe, The Wall Street Journal reported Jan. 22.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
